In a relative bioavailability study in 15 healthy adult male volunteers levocarnitine tablets were found to be bio-equivalent to levocarnitine oral solution. Following 4 days of dosing with 6 tablets of levocarnitine 330 mg b.i.d. or 2 g of levocarnitine oral solution twice daily, the maximum plasma concentration (C max) was about 80 μmol/L and the time to maximum plasma concentration (T max) occurred at 3.3 hours. Deprecated function: implode(): Passing glue string after array is deprecated. Swap the parameters in drupal_get_feeds() (line 394 of /home/vivatuneuk/domains/vivatuneuk.co.uk/public_html/includes/common.inc). The steady state volume of distribution (Vss) of an intravenously administered dose, above endogenous baseline levels, was calculated to be 29.0 +/- 7.1L. However this value is predicted to be an underestimate of the true Vss. Protein binding If a severe hypersensitivity reaction occurs, discontinue CARNITOR ® treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering CARNITOR ® to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction. PRECAUTIONS General The word carnitine is derived from the Latin word carnus, meaning meat. The redder the meat, the higher the carnitine content.

Dive into the robust benefits of L-Carnitine, from cardiovascular support to enhanced immunity and beyond. 4. Tailored for Dietary Restrictions: Tamai I, China K, Sai Y, Kobayashi D, Nezu J, Kawahara E, Tsuji A: Na(+)-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim Biophys Acta. 2001 Jun 6;1512(2):273-84. [ Article] Marzo, A., Arrigoni Martelli, E., Mancinelli, A., Cardace, G., Corbelletta, C., Bassani, E. and Solbiati, M. 1991. Protein binding of L-carnitine family components. Eur. J. Drug Met. Pharmacokin., Special Issue III: 364-368.The table below lists the adverse events that have been reported in two double-blind, placebo-controlled trials in patients on chronic hemodialysis. Events occurring at ≥5% are reported without regard to causality. Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following CARNITOR ® administration, mostly in patients with end stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of CARNITOR ®. Although research to date suggests that L-carnitine is indicated for these conditions, there isn’t much conclusive evidence to support the claims. In a pharmacokinetic study where five normal adult male volunteers received an oral dose of [ 3H-methyl]- L-carnitine following 15 days of a high carnitine diet and additional carnitine supplement, 58 to 65% of the administered radioactive dose was recovered in the urine and feces in 5 to 11 days. Maximum concentration of [ 3H-methyl]-L-carnitine in serum occurred from 2.0 to 4.5 hr after drug administration. Major metabolites found were trimethylamine N-oxide, primarily in urine (8% to 49% of the administered dose) and [ 3H]-γ-butyrobetaine, primarily in feces (0.44% to 45% of the administered dose). Urinary excretion of levocarnitine was about 4 to 8% of the dose. Fecal excretion of total carnitine was less than 1% of the administered dose. 10

For carnitine deficiency, the initial dose is 300 to 400 mg/kg in 6 to 8 equal doses over a 24-hour period. This is followed by maintenance doses of 50 mg/kg daily. Aceclofenac may decrease the excretion rate of Levocarnitine which could result in a higher serum level.It is recommended that a plasma carnitine concentration be obtained prior to beginning this parenteral therapy. Weekly and monthly monitoring is recommended as well. This monitoring should include blood chemistries, vital signs, plasma carnitine concentrations (the plasma free carnitine concentration should be between 35 and 60 μmol/L) and overall clinical condition. Pharmacokinetic and clinical studies with levocarnitine have shown that administration of levocarnitine to ESRD patients on hemodialysis results in increased plasma levocarnitine concentrations.